What Insurance Does a Digital Cytology Platform Need?

A digital cytology platform needs coverage for two identities at once: a clinical laboratory service and, where its software reads or flags slides, a medical device. Most are placed by generalist brokers as one or the other, and the gap sits exactly where the platform is most valuable, the algorithm that interprets the slide.

The Cytology Exposure Starts With the False Negative

Cytology is screening, and the dominant claim is the missed finding. A false negative on a Pap or other screening slide can surface years later as a delayed-diagnosis claim. That is a professional liability exposure for the lab, and it is severe precisely because the harm appears long after the slide was read. A digital cytology platform inherits that exposure the moment its output influences whether a slide is flagged for human review, because the screening decision now runs partly through software. The long latency means the coverage that responds is the one in force at the time of the read, not the time the claim arrives, so continuity matters.

Where the Device Classification Changes the Picture

When the platform only digitizes and displays slides, it looks like lab software. When an algorithm scores, flags, or prioritizes slides and that output shapes the read, it takes on a medical device character, and a product liability exposure comes with it. A platform placed purely as a lab, on professional liability alone, has no clear answer to a claim framed as a device defect, which is the same seam behind AI device product liability. The classification is not always obvious, and the FDA’s posture on AI-enabled cytology can change, so the program should not quietly assume the lighter category.

The Remote-Review and Data Layer

Digital cytology added an operational wrinkle in 2026: a lab that reviews digital cytology images at a remote location now needs a separate CLIA certificate for that location. That is a compliance step, but it also marks where the work happens, and the work generates images and patient data that carry a cyber and HIPAA exposure on top of the clinical and device questions. A platform holding cytology images for multiple lab clients is also likely a business associate, which pulls in the contractual side of that exposure and the notice duties that come with it.

Building the Program

A digital cytology platform usually needs professional liability for the screening and interpretation work, product liability and technology errors and omissions coordinated for the algorithm and the platform, and cyber with HIPAA in mind for the images and data. This is the cytology-specific case of the broader pattern in what a digital pathology company needs, and it starts from the same place as the core insurance a CLIA-certified lab carries. The mistake to avoid is letting the platform be filed as one thing, because the AI that makes it valuable is exactly what crosses the categories.

What to Do Now

Map the platform against both identities, lab service and device, and ask which policy answers a false-negative claim, an algorithm-defect claim, and a data breach. Confirm the device question is settled in the wording rather than left to interpretation, and confirm the remote-review and business-associate posture is reflected in the cyber and HIPAA program. Then revisit as the FDA’s stance on AI cytology develops, because the classification can move and the coverage should not lag it.

Before your next renewal, have the platform reviewed as both a laboratory and a device at the same time. A specialty review through Tower Street Insurance can confirm a digital cytology platform is covered across both of the things it is.